Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3

Molecular Biology Reports

Volumn 39, Issue 10, 2012, Pages 9299-9306

  Shi, HuiRong ^a   Liu, HuiNa ^a,b   Zhao, GuoQiang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

DLC1; FAK; OVCAR 3; pGFP siCon DLC1 vector; pGFP siFAK DLC1 vector; siRNA; Transfection

Indexed keywords

CASPASE 3; CASPASE 9; MESSENGER RNA; ONCOPROTEIN; PROTEIN DLC1; PROTEIN FAK; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DLC1 GENE; DNA HAIRPIN; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME ASSAY; FAK GENE; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENE VECTOR; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA TRANSCRIPTION; RNA TRANSLATION; RNA TRANSPORT; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; FEMALE; FOCAL ADHESION KINASE 1; GENE KNOCKDOWN TECHNIQUES; GTPASE-ACTIVATING PROTEINS; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84868545438     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1724-7     Document Type: Article

References (44)

1. Markman M (2008) Pharmaceutical management of ovarian cancer: current status. Drugs 68:771-789
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502
4. Vidal L, Attard G, Kaye S, De Bono J (2004) Reversing resistance to targeted therapy. J Chemother 16(Suppl 4):7-12
5. Richardson A, Kaye SB (2005) Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 8(5):311-321
6. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117:3623-3632
7. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75-86
8. Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J 277:4814-4827
9. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74(12):5463-5467
10. Hanahan D (1983) Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166:557-580
11. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
12. Zhou X, Thorgeirsson SS, Popescu NC (2004) Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23(6):1308-1313
13. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, Popescu NC (2007) DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 11(5):1185-1207
14. Kim TY, Lee JW, Kim HP, Jong HS, Kim TY, Jung M, Bang YJ (2007) DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 355(1):72-77
15. Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye MA (2008) Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res 68:8743-8751
16. Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T, Ho SM (2005) Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesteroneregulated genes for ovarian cancer cells by gene profiling. Oncogene 24:1774-1787
17. Feng MH, Huang B, Du ZG, Xu XP, Chen Z (2011) DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep 38:1915-1920
18. Baik S-H, Jee B-K, Choi J-S, Yoon H-K, Lee K-H, Kim YH, Lim Y (2009) DNA profiling by array comparative genomic hybridization (CGH) of peripheral blood mononuclear cells (PBMC) and tumor tissue cell in non-small cell lung cancer (NSCLC). Mol Biol Rep 36:1767-1778
19. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249-256
20. Volberg T, Romer L, Zamir E, Geiger B (2001) pp 60 (c-src) and related tyrosine kinases: a role in the assembly and reorganization of matrix adhesions. J Cell Sci 114:2279-2289
21. Zhao JH, Reiske H, Guan JL (1998) Regulation of the cell cycle by focal adhesion kinase. J Cell Biol 143:1997-2008
22. McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, Hodivala-Dilke K, Metzger D, Chambon P, Grant SG, Frame MC (2004) Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev 18:2998-3003
23. Li N, Li Q, Zhou XD, Kolosov VP, Perelman JM (2012) Chronic mechanical stress induces mucin 5AC expression in human bronchial epithelial cells through ERK dependent pathways. Mol Biol Rep 39:1019-1028
24. He S, Zhang DC, Cheng F, Gong FH, Guo YN (2009) Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep 36:2153-2163
25. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, Schlaepfer DD, Alaoui-Jamali MA (2005) FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171:505-516
26. Mitra SK, Lim ST, Chi A, Schlaepfer DD (2006) Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 25:4429-4440
27. Van Nimwegen MJ, Verkoeijen S, Van Buren L, Burg D, Van De Water B (2005) Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 65:4698-4706
28. Schaller MD (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540:1-21
29. Schlaepfer DD, Hauck CR, Sieg DJ (1999) Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71:435-478
30. Zhao J, Zheng C, Guan J (2000) Pyk2 and FAK differentially regulate progression of the cell cycle. J Cell Sci 113:3063-3072
31. Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, Brenner DA, Rippe RA (2003) The role of focal adhesion kinasephosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 278:8083-8090
32. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, Cui Z, Thannickal VJ (2007) Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 19:761-771
33. Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, Tsuruo T, Beaulieu JF, Gauthier R, Vezina A, Villeneuve L, Vachon PH (2007) Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol 212:717-728
34. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26:1338-1345
35. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE (2002) Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62
36. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43
37. Fernandes-Alnemri T, Litwack G, Alnemri ES (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761-30764
38. Tormanen-Napankangas U, Soini Y, Kahlos K, Kinnula V, Paakko P (2001) Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer 93:192-198
39. Hsia JY, Chen CY, Chen JT, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Miaw J (2003) Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol 29:44-48
40. Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC (2003) Expression of surviving and caspase-3 in gastric cancer. Dig Dis Sci 48:266-271
41. Degterev A, Yuan J (2008) Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9(5):378-390
42. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949-957
43. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255-288
44. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249